ANNALS OF ONCOLOGY

医学 肿瘤学

  • 影响指数:51.717
  • 中科院分区:医学 1区[Top] 医学 1 区
  • 审稿周期:平均1.83月
  • 自引率:15.3%
  • 录取率:20.83%
  • ISSN:2190-572X
  • 发刊频率:暂无数据
  • 年文章数:454
  • 国人占比:10.76%
  • 期刊网址:点击查看
  • 研究方向:肿瘤;癌症;乳腺癌
  • 期刊攻略
  • IF变化趋势
  • 期刊占比
  • 最新文章

期刊简介

3 BIOTECH杂志暂不明确行业,暂不明确子行业的级别不明杂志

收稿要求

暂无数据

建议

杂志水平一般,也很冷门,关注人少,审稿周期可能也不一定快,如果文章质量不佳,或时间不紧的话,可以考虑考虑。

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

DOI:10.1016/j.annonc.2022.06.004

发表时间:2022 Jun 15

作者:Dimitriou F;Namikawa K;Reijers ILM;Buchbinder EI;Soon JA;Zaremba A;Teterycz P;Mooradian MJ;Armstrong E;Nakamura Y;Vitale MG;Tran LE;Bai X;Allayous C;Provent-Roy S;Indini A;Bhave P;Farid M;Kähler KC;Mehmi I;Atkinson V;Klein O;Stonesifer CJ;Zaman F;Haydon A;Carvajal RD;Hamid O;Dummer R;Hauschild A;Carlino MS;Mandala M;Robert C;Lebbe C;Guo J;Johnson DB;Ascierto PA;Shoushtari AN;Sullivan RJ;Cybulska-Stopa B;Rutkowski P;Zimmer L;Sandhu S;Blank CU;Lo SN;Menzies AM;Long GV

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

DOI:10.1016/j.annonc.2022.06.008

发表时间:2022 Jun 25

作者:André T;Lonardi S;Wong KYM;Lenz HJ;Gelsomino F;Aglietta M;Morse MA;Van Cutsem E;McDermott R;Hill A;Sawyer MB;Hendlisz A;Neyns B;Abdullaev S;Memaj A;Lei M;Dixon M;Kopetz S;Overman MJ

The deleterious effect of acetaminophen in cancer immunotherapy.

DOI:10.1016/j.annonc.2022.06.012

发表时间:2022 Jun 25

作者:Berraondo P;Sullivan RJ

Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer.

DOI:10.1016/j.annonc.2022.06.007

发表时间:2022 Jun 25

作者:Brunet M;Crombé A;Cousin S;Vanhersecke L;Le Loarer F;Bessede A;Italiano A

公众号